Nicole Duncan

Dr. Nicole Duncan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
SWSydney Wendt
Sydney Wendt
ZAZainub Abdullah
Zainub Abdullah
SBSpencer Barrett
Spencer Barrett
CDCyrus Daruwalla
Cyrus Daruwalla
JGJonathan A. Go
Jonathan A. Go
ALAndrew G Lee
Andrew G Lee

26 November 2025 in Reports
Verified
Journal Article
Open access
PDF file
MMMoon Moon
Moon Moon
NDNicole Duncan
Nicole Duncan
JYJeff Yorio
Jeff Yorio
EMEthan Meltzer
Ethan Meltzer
MAMoe Aung
Moe Aung
Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immune-related adverse events (IRAEs), including orbitopathy. To date, only a handful of cases have described the treatment of thyroid eye disease secondary to mAbs, and even fewer have described how to treat refractory disease. Case Presentation: We are illustrating two cases in this report: a 73-year-old woman who developed thyroid eye disease (TED) after nivolumab therapy for melanoma, and a 36-year-old man who presented with TED following alemtuzumab treatment for multiple sclerosis. Both patients failed corticosteroid therapy but showed a significant improvement with teprotumumab, an anti-insulin-like growth factor (IGF)-1 receptor mAb. Conclusions: These cases highlight underrecognized orbital IRAEs linked to mAb therapy and demonstrate teprotumumab’s potential as an effective option for steroid-refractory thyroid orbitopathy. Clinicians should maintain an awareness of orbital complications in patients receiving mAbs to enable prompt diagnosis and intervention, minimizing visual morbidity. Further studies are needed to clarify the pathogenesis of mAb-associated orbitopathy and to establish evidence-based treatment protocols for these rare but impactful complications.

20 February 2026 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
NDNicole Duncan
Nicole Duncan
DRDonovan Reed
Donovan Reed
CHClio Armitage Harper
Clio Armitage Harper
TNTanuj Nakra
Tanuj Nakra